Search results

Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults

Type

Highly specialised technologies guidance

Published

24 February 2021

Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography

Type

Diagnostics guidance

Published

17 March 2021

Evidence-based recommendations on Leukomed Sorbact for preventing surgical site infection after caesarean section or vascular surgery

Type

Medical technologies guidance

Published

03 February 2021

Evidence-based recommendations on the VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal

Type

Medical technologies guidance

Published

27 January 2021

Evidence-based recommendations on Alpha-Stim AID for anxiety disorders

Type

Medical technologies guidance

Published

08 March 2021

Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding

Type

Medical technologies guidance

Published

31 March 2021

Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)

Type

Technology appraisal guidance

Last updated

08 February 2021

Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults

Type

Technology appraisal guidance

Published

03 February 2021

Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults

Type

Technology appraisal guidance

Published

03 February 2021

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adult

Type

Technology appraisal guidance

Published

27 January 2021

Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been

Type

Technology appraisal guidance

Published

27 January 2021

Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults

Type

Technology appraisal guidance

Published

24 February 2021

NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals

Type

Technology appraisal guidance

Published

24 February 2021

Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults

Type

Technology appraisal guidance

Published

24 February 2021

Evidence-based recommendations on autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma in adults who have

Type

Technology appraisal guidance

Published

24 February 2021

Evidence-based recommendations on niraparib for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary

Type

Technology appraisal guidance

Published

17 February 2021

NICE is unable to make a recommendation on pembrolizumab (Keytruda) for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when

Type

Technology appraisal guidance

Published

17 February 2021

NICE is unable to make a recommendation on vernakalant (Brinavess) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. This

Type

Technology appraisal guidance

Published

17 February 2021

Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung

Type

Technology appraisal guidance

Published

10 March 2021

Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults

Type

Technology appraisal guidance

Published

10 March 2021

Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in

Type

Technology appraisal guidance

Published

17 March 2021

Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults

Type

Technology appraisal guidance

Published

03 March 2021

Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple

Type

Technology appraisal guidance

Published

03 March 2021

NICE is unable to make a recommendation on blinatumomab (Blincyto) for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia in

Type

Technology appraisal guidance

Published

31 March 2021

Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally

Type

Technology appraisal guidance

Published

31 March 2021

Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating

Type

Technology appraisal guidance

Published

31 March 2021

Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and

Type

Technology appraisal guidance

Published

31 March 2021